Vincent John. Murphy
La Trobe University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vincent John. Murphy.
Infection and Immunity | 2009
Danielle I. Stanisic; Jack S. Richards; Fiona J. McCallum; Pascal Michon; Christopher L. King; Sonja Schoepflin; Paul R. Gilson; Vincent John. Murphy; Robin F. Anders; Ivo Mueller; James G. Beeson
ABSTRACT Substantial evidence indicates that antibodies to Plasmodium falciparum merozoite antigens play a role in protection from malaria, although the precise targets and mechanisms mediating immunity remain unclear. Different malaria antigens induce distinct immunoglobulin G (IgG) subclass responses, but the importance of different responses in protective immunity from malaria is not known and the factors determining subclass responses in vivo are poorly understood. We examined IgG and IgG subclass responses to the merozoite antigens MSP1-19 (the 19-kDa C-terminal region of merozoite surface protein 1), MSP2 (merozoite surface protein 2), and AMA-1 (apical membrane antigen 1), including different polymorphic variants of these antigens, in a longitudinal cohort of children in Papua New Guinea. IgG1 and IgG3 were the predominant subclasses of antibodies to each antigen, and all antibody responses increased in association with age and exposure without evidence of increasing polarization toward one subclass. The profiles of IgG subclasses differed somewhat for different alleles of MSP2 but not for different variants of AMA-1. Individuals did not appear to have a propensity to make a specific subclass response irrespective of the antigen. Instead, data suggest that subclass responses to each antigen are generated independently among individuals and that antigen properties, rather than host factors, are the major determinants of IgG subclass responses. High levels of AMA-1-specific IgG3 and MSP1-19-specific IgG1 were strongly predictive of a reduced risk of symptomatic malaria and high-density P. falciparum infections. However, no antibody response was significantly associated with protection from parasitization per se. Our findings have major implications for understanding human immunity and for malaria vaccine development and evaluation.
Infection and Immunity | 2006
Andrew M. Coley; Kathy Parisi; Rosella. Masciantonio; J. Hoeck; Joanne L. Casey; Vincent John. Murphy; Karen S. Harris; Adrian H. Batchelor; Robin F. Anders; Michael Foley
ABSTRACT Apical membrane antigen 1 (AMA1) is currently one of the leading malarial vaccine candidates. Anti-AMA1 antibodies can inhibit the invasion of erythrocytes by Plasmodium merozoites and prevent the multiplication of blood-stage parasites. Here we describe an anti-AMA1 monoclonal antibody (MAb 1F9) that inhibits the invasion of Plasmodium falciparum parasites in vitro. We show that both reactivity of MAb 1F9 with AMA1 and MAb 1F9-mediated invasion inhibition were strain specific. Site-directed mutagenesis of a fragment of AMA1 displayed on M13 bacteriophage identified a single polymorphic residue in domain I of AMA1 that is critical for MAb 1F9 binding. The identities of all other polymorphic residues investigated in this domain had little effect on the binding of the antibody. Examination of the P. falciparum AMA1 crystal structure localized this residue to a surface-exposed α-helix at the apex of the polypeptide. This description of a polymorphic inhibitory epitope on AMA1 adds supporting evidence to the hypothesis that immune pressure is responsible for the polymorphisms seen in this molecule.
Journal of Molecular Biology | 2008
Xuecheng Zhang; Matthew A. Perugini; Shenggen Yao; Christopher G. Adda; Vincent John. Murphy; Andrew Low; Robin F. Anders; Raymond S. Norton
Merozoite surface protein 2 (MSP2), one of the most abundant proteins on the surface of the merozoite stage of Plasmodium falciparum, is a potential component of a malaria vaccine, having shown some efficacy in a clinical trial in Papua New Guinea. MSP2 is a GPI-anchored protein consisting of conserved N- and C-terminal domains and a variable central region. Previous studies have shown that it is an intrinsically unstructured protein with a high propensity for fibril formation, in which the conserved N-terminal domain has a key role. Secondary structure predictions suggest that MSP2 contains long stretches of random coil with very little alpha-helix or beta-strand. Circular dichroism spectroscopy confirms this prediction under physiological conditions (pH 7.4) and in more acidic solutions (pH 6.2 and 3.4). Pulsed field gradient NMR diffusion measurements showed that MSP2 under physiological conditions has a large effective hydrodynamic radius consistent with an intrinsic pre-molten globule state, as defined by Uversky. This was supported by sedimentation velocity studies in the analytical ultracentrifuge. NMR resonance assignments have been obtained for FC27 MSP2, allowing the residual secondary structure and backbone dynamics to be defined. There is some motional restriction in the conserved C-terminal region in the vicinity of an intramolecular disulfide bond. Two other regions show motional restrictions, both of which display helical structure propensities. One of these helical regions is within the conserved N-terminal domain, which adopts essentially the same conformation in full-length MSP2 as in corresponding peptide fragments. We see no evidence of long-range interactions in the full-length protein. MSP2 associates with lipid micelles, but predominantly through the N-terminal region rather than the C terminus, which is GPI-anchored to the membrane in the parasite.
Journal of Proteomics & Bioinformatics | 2008
R. S. Norton; X. Zhang; Matthew A. Perugini; X. Yang; A. Low; S. Yao; Christopher G. Adda; Vincent John. Murphy; Robin F. Anders
Merozoite surface protein 2 (MSP2) is synthesized by asexual blood stages of the human malaria parasite Plasmodium falciparum as a GPI-anchored protein. It has been implicated in erythrocyte invasion and is being developed as a vaccine candidate. NMR, light scattering, CD and sedimentation velocity measurements all show that recombinant MSP2 is disordered in solution and adopts an extended conformation. NMR has also been used to examine peptides corresponding to sequences in the conserved N-terminal region of MSP2. A 25-residue peptide corresponding to the entire N-terminal region contains nascent helical and turn-like structures (1). An 8-residue peptide from the centre of the N-terminal domain also formed a turn-like structure (2). Both peptides formed fibrils that were similar to the amyloid-like fibrils formed by full-length MSP2. It appears that this N-terminal conserved region of MSP2 plays a key role in fibril formation. Mutational analyses are being pursued to understand the role of this region in structure and fibril formation (1). NMR resonance assignments have been obtained for full-length MSP2, allowing the residual secondary structure and backbone dynamics to be defined (3). There is some motional restriction in the conserved C-terminal region in the vicinity of an intramolecular disulfide bond. Two other regions show motional restrictions, both of which display helical structure propensities. One of these helical regions is within the conserved N-terminal domain, which adopts essentially the same conformation in full-length MSP2 as in corresponding peptide fragments. We see no evidence of long-range interactions in the full-Volume S2:070-071(2008)
Vaccine | 2005
Allan Saul; Greg Lawrence; Anthony Allworth; Suzanne L. Elliott; Karen Anderson; Christine M. Rzepczyk; Laura B. Martin; Darrin Taylor; Damon P. Eisen; David O. Irving; David Pye; Pauline E. Crewther; Anthony N. Hodder; Vincent John. Murphy; Robin F. Anders
Structure | 2007
Kylie Anne Henderson; Victor A. Streltsov; Andrew M. Coley; Olan Dolezal; Peter J. Hudson; Adrian H. Batchelor; Aditi Gupta; Tao Bai; Vincent John. Murphy; Robin F. Anders; Michael Foley; Stewart D. Nuttall
Journal of Molecular Biology | 2005
A. Gupta; T. Bai; Vincent John. Murphy; P. Strike; Robin F. Anders; A. Batchelor
Archive | 2003
Vincent John. Murphy; Rosella. Masciantonio; Andrew M. Coley; Joanne L. Casey; Ross. Weston; Michael. Foley; M. Alderton; Robin. Anders
Archive | 2003
Anthony N. Hodder; Margaret Sunde; Lynne J. Waddington; Solie. Abdulnour; Kleopatra. Vingas; Vincent John. Murphy; Christopher G. Adda; Robin. Anders; Rosella. Masciantonio; ComBio
Archive | 2003
Robin. Anders; Vincent John. Murphy; Anthony N. Hodder; Lynne J. Waddington; Christopher G. Adda
Collaboration
Dive into the Vincent John. Murphy's collaboration.
Commonwealth Scientific and Industrial Research Organisation
View shared research outputs